Medicis Pharmaceutical (MRX) Stock Price, News & Analysis

Company Overview

Medicis Pharmaceutical Corporation (Medicis) together with its wholly owned subsidiaries is an independent specialty pharmaceutical company engaged in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States and Canada. Medicis offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles. Its brands are DYSPORT (abobotulinumtoxinA) 300 Units for Injection, PERLANE Injectable Gel, RESTYLANE Injectable Gel, SOLODYN (minocycline HCl, USP) Extended Release Tablets, VANOS (fluocinonide) Cream 0.1%, ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel and ZYCLARA (imiquimod) Cream 3.75% and 2.5%. As of December 31, 2011, it offered 27 branded products. On December 2, 2011, it acquired Graceway Pharmaceuticals, LLC (Graceway). On November 1, 2011, Medicis sold Medicis Technologies Corporation, formerly LipoSonix, Inc., to Solta Medical, Inc. (Solta).

Key Stats

• Today's Range: $32.54 to $33.33
• 50-Day Range: N/A
• 52-Week Range: $18.13 to $49.34
• Volume: 415,945 shs
• Average Volume: 644,091 shs
• Market Capitalization: $2.39 billion
• P/E Ratio: N/A
• Dividend Yield: 1.65%
• Price Target: $45.14
• Consensus Rating: Moderate Buy

Medicis Pharmaceutical Stock Analysis - MarketRank™

Medicis Pharmaceutical scored higher than 30% of companies evaluated by MarketBeat, and ranked 841st out of 946 stocks in the finance sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Medicis Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Medicis Pharmaceutical has a consensus price target of $45.14, representing about 32.9% upside from its current price of $33.96.

Amount of Analyst Coverage

Medicis Pharmaceutical has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -0.34%

Earnings Growth

Earnings for Medicis Pharmaceutical are expected to decrease by -0.34% in the coming year, from $2.94 to $2.93 per share.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for MRX.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Medicis Pharmaceutical pays a meaningful dividend of 1.44%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Medicis Pharmaceutical does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Medicis Pharmaceutical will have a dividend payout ratio of 19.11% next year. This indicates that Medicis Pharmaceutical will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for MRX.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 4 news articles for Medicis Pharmaceutical this week, compared to 1 article on an average week.

Search Interest

Only 8 people have searched for MRX on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.

MarketBeat Follows

1 people have added Medicis Pharmaceutical to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Medicis Pharmaceutical insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.79% of the stock of Medicis Pharmaceutical is held by insiders.

MRX Stock Analysis - Frequently Asked Questions

How were Medicis Pharmaceutical's earnings last quarter?

Medicis Pharmaceutical Corp (NYSE:MRX) released its quarterly earnings results on Wednesday, August, 13th. The healthcare company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.09. The company's revenue was up 18.5% compared to the same quarter last year.

When did Medicis Pharmaceutical IPO?

Medicis Pharmaceutical (MRX) raised $292 million in an initial public offering (IPO) on Thursday, April 25th 2024. The company issued 15,384,615 shares at $19.00 per share.

Who are Medicis Pharmaceutical's major shareholders?

Top institutional shareholders of Medicis Pharmaceutical include State of Tennessee Department of Treasury (0.17%), SG Americas Securities LLC (0.03%) and Simplex Trading LLC.

What other stocks do shareholders of Medicis Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Medicis Pharmaceutical investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 8/13/2025
• Record date for 9/11 Dividend: 8/26/2025
• Ex-Dividend for 9/11 Dividend: 8/26/2025
• Today: 9/11/2025
• Dividend Payable: 9/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Finance
• Industry: Security & commodity brokers, dealers, exchanges & services
• Sub-Industry: N/A
• Current Symbol: NYSE:MRX
• CIK: 859368
• Web: www.Medicis.com
• Phone: +1-212-5992000
• Fax: N/A
• Employees: 2,074
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Medicis Pharmaceutical: $45.14
• High Price Target: $54.00
• Low Price Target: $34.00
• Potential Upside/Downside: +31.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 1.18
• Current Ratio: 1.04
• Quick Ratio: 1.08

Sales & Book Value

• Annual Sales: $1.24 billion
• Price / Sales: 1.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 70,290,000
• Free Float: 67,627,000
• Market Cap: $2.42 billion
• Optionable: Optionable
• Beta: N/A